Treatment of Metastatic Triple-Negative Breast Cancer
The Pharma Data
MARCH 25, 2021
Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. SG contains a genotoxic component and can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. About the ASCENT Study. About Sacituzumab Govitecan-Hziy.
Let's personalize your content